2095.7000 6.70 (0.32%)
NSE Mar 24, 2026 15:50 PM
Volume: 540.5K
 

2095.70
0.32%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Number of FII/FPI investors increased from 401 to 422 in Dec 2025 qtr.
More from Glenmark Pharmaceuticals Ltd.
Recommended